Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up

Abstract Background Following a 30-year development process, RTS,S/AS01E (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating the delivery of RTS,S/AS01E through routine n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nicolas Praet, Kwaku Poku Asante, Marie-Cecile Bozonnat, Elaine Jacqueline Akité, Patrick Odum Ansah, Laurence Baril, Owusu Boahen, Yolanda Guerra Mendoza, Valerie Haine, Simon Kariuki, Mathieu Lamy, Kenneth Maleta, Randy Mungwira, Latif Ndeketa, Abraham Oduro, Bernhards Ogutu, Fredrick Olewe, Martina Oneko, Mattéa Orsini, Francois Roman, Edith Roset Bahmanyar, Dominique Rosillon, Lode Schuerman, Valentine Sing’oei, Dianne J. Terlouw, Stéphanie Wéry, Walter Otieno, Jean-Yves Pirçon
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2022-04-01
Colecção:Malaria Journal
Assuntos:
Malaria
RTS,S/AS01E
Plasmodium falciparum
Safety
Effectiveness
Impact
Acesso em linha:https://doi.org/10.1186/s12936-022-04144-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados